Biochemical analysis and lipid peroxidation in liver ischemic preconditioning.

BACKGROUND: Hepatic surgery requires, under diverse circumstances, periods of ischemia and reperfusion (I-R) such as those present in liver resection, hepatic injury, and liver transplantation. The objective of the present work was to conduct an experimental study to evaluate the effect of hepatic preconditioning (HPC) on modulation of the I-R injury. METHODS: Male Wistar rats were distributed into the following three study groups: group 1, simulated or sham; group 2, submitted to a 30-min period of total warm ischemia and a reperfusion phase, and group 3, in which we carried out 10-min preconditioning of warm ischemia and 10 min of reperfusion prior to the total ischemia period for a total of 60 min and the reperfusion phase. We obtained liver biopsies for thiobarbituric acid reactive substances (TBARS) (MDA, thiobarbituric acid adducts) and for blood sample determinations in serum of liver-cell enzymes such as alanine aminotransferase and aspartate aminotransferase during a 24-h time course. RESULTS: We observed a decrease in the variables studied in group 3 (HPC) as well as of serum liver enzymes and TBARS levels such as indirect oxidative stress indicators upon comparison with group 2 animals submitted to total hepatic I-R. CONCLUSIONS: HPC is an efficient surgical strategy for decreasing the elevation of hepatic enzymes and indirect lipoperoxidation indicators in an I-R model. Controlled clinical studies should be performed to determine its functional properties and clinical applicability.

Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass.

BACKGROUND: To define the incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. METHODS: A retrospective study was conducted for all patients undergoing laparoscopic Roux-en-Y gastric bypass from 2004 to 2006. The data collected included patient demographics, body mass index, operative time, conversion rate, thromboprophylaxis measures, hospital stay, and complications. RESULTS: Of the 618 patients included in the study, 451 (73%) were women and 167 (27%) were men, with a mean age of 44 years (range 18-78). The preoperative body mass index was 49 kg/m(2) (range 35-90). All patients received the same thromboprophylaxis regimen. All surgical procedures were performed and completed laparoscopically, with a mean operative time of 93 minutes (range 50-196). All patients underwent lower extremity color Doppler ultrasonography within the first 24 hours after the surgical procedure. The mean hospital stay was 4 days (range 2-21). The most common in-hospital complication was basal atelectasis in 52 patients (8.4%), followed by gastrointestinal bleeding in 10 (1.6%), and anastomotic leak in 6 (1%). The postoperative follow-up visits were done at 2, 8, 12, 24, and 52 weeks after surgery; no mortality occurred. The overall rate of deep vein thrombosis in the group of 500 consecutive patients was .2%, with no clinically significant pulmonary embolism; 9 patients presented with postoperative bleeding. CONCLUSION: The overall rate of deep vein thrombosis in this group of patients was low, most probably because of the use of thromboprophylaxis.

Factors in the pathophysiology of the liver ischemia-reperfusion injury.

Hepatic ischemia-reperfusion injury is commonplace in liver surgery, particularly in hepatic transplantation, hepatic resection, and trauma. The signaling events contributing to local hepatocellular damage are diverse and complex and involve the interaction between hepatocytes, sinusoidal endothelial cells, Kupffer cells, as well as infiltrating neutrophils, macrophages, and platelets. Signaling mediators include cytokines, reactive oxygen and nitrogen species, calcium, complement, and several transcription factors. The purpose of this review article was to summarize the factors that contribute to the pathophysiology of hepatic ischemia-reperfusion injury.

The ABC System: a simplified classification system for small bowel obstruction after laparoscopic Roux-en-Y gastric bypass.

Small bowel obstruction (SBO) after bariatric surgery is well documented. Although infrequent, it can be associated with considerable morbidity and mortality. The laparoscopic approach to Roux-en-Y gastric bypass (LRYGB) has gained widespread popularity for the treatment of morbid obesity since its first description in 1994. One of the theoretical advantages of a minimally invasive technique is reduced intraabdominal adhesions and, consequently, diminution in the incidence of SBO. However, the laparoscopic approach demonstrates a similar rate of obstruction to the open procedure. In this review, an electronic literature search was undertaken of Medline, Embase, and Cochrane databases for the period January 1990 to October 2006 on the history, presentation, clinical evaluation, preoperative diagnostic techniques, and management of SBO after LRYGB compared to the open approach.

Trasplante de pulmón / Lung transplantation

Lung transplantation (LT) has evolved to become an Important alternative in the management of patients with end-stage pulmonary disease and chronic respiratory failure. The beginnings of this technique can be traced back to the experiments of Carrel and Guthrie over a hundred years ago. However, it was not until 1963 when the first clinical experience was performed by Hardy. Clinical success did not arrive until the 1980's thanks to the works of the Toronto Lung Transplant Group. Well established criteria have been described in order to consider a patient as a potential candidate to receive a lung. Several diseases are capable of causing terminal lung damage and in general they can be classified according to their origin as obstructive (COPD, emphysema), restrictive (fibrosis), chronic infectious (cystic fibrosis, bronquiectasis), and vascular (primary pulmonary hypertension). The most frecuent diagnosis is COPD. Clynically relevant modes of LT include the implant of one lung (single LT), or both lungs (bilateral sequential LT). Transplantation of the cardiopulmonary block is reserved for special situations and lobar transplantation is still considered experimental. Donor condition is essential to the success of LT. The potential donor patient frecuently suffers deterioration in lung function due to edema formation or infection and both complications restrict lung's using for transplantation. Lung preservation is also limited to a short period of time which rarely exceeds 6 hours in spite of specially-designed preservative solutions such as the low potassium dextran. Outcome after LT shows current one-year survival between 65-70% with reduction to 40-45% after five years. Mortality within the first year is usually related to primary graft failure and infection. Long-term survival depends on controlling infectious problems due to immunosupresion as well as the development of bronchilitis obliterans as a manifestation of chronic rejection. LT is a therapeutic modality reserved for selected patients with chronic respiratory failure due to end-stage lung disease.

El trasplante de pulmón se ha desarrollado como parte del manejo de pacientes con enfermedad pulmonar terminal que presentan insuficiencia respiratoria. Si bien los inicios de la técnica se encuentran en los experimentos de Carrel y Guthrie a principios del siglo XX, no fue sino hasta 1963 en que Hardy efectuó el primer trasplante pulmonar. Sin embargo, el éxito clínico no se tradujo en realidad sino hasta fines de los años ochenta gracias al esfuerzo del Grupo de Trasplante de la Universidad de Toronto. Existen criterios bien establecidos para considerar cuando un enfermo pulmonar terminal se encuentra en condiciones de ameritar un trasplante. Las patologías capaces de producir daño pulmonar terminal son muy variadas, pero en términos generales pueden dividirse en aquellas de origen obstructivo (EPOC, enfisema), las de tipo intersticial (fibrosis pulmonar), las de origen infeccioso crónico (fibrosis quística, bronquiectasias) y las de patología vascular (hipertensión pulmonar primaria). Con mucho el diagnóstico más frecuente es la EPOC. Es posible trasplantar un solo pulmón (trasplante unilateral) o bien los dos pulmones (trasplante bilateral secuencial). El trasplante del bloque cardiopulmonar se reserva para situaciones especiales y el trasplante lobar se considera aún experimental. Las condiciones del donador son especialmente importantes y constituyen muchas veces el principal obstáculo a vencer debido al deterioro pulmonar que sufren estos pacientes durante el manejo previo a la toma de decisión sobre la donación de los órganos. El deterioro pulmonar y la infección sobreagregada son los principales problemas que limitan la procuración de pulmones. La preservación pulmonar aún se encuentra limitada a un tiempo corto que rara vez excede las seis horas a pesar de utilizar soluciones especialmente diseñadas como lo es la de dextrán baja en potasio. Los resultados muestran una sobrevida a un año de entre 65-70% disminuyendo a 40-45% a los cinco años. Las causas de mortalidad dentro del primer año se relacionan con falla primaria del injerto, así como infecciones oportunistas. A largo plazo, además de infecciones oportunistas por la inmunosupresión se agrega el problema del desarrollo de bronquiolitis obliterante como manifestación de rechazo crónico. El trasplante pulmonar es una modalidad de manejo adecuada para pacientes seleccionados con falla respiratoria crónica secundaria a enfermedad terminal, sin embargo, se encuentra limitada por la disponibilidad de órganos para trasplantar.

[Lung transplantation]. / Trasplante de pulmón.

Lung transplantation (LT) has evolved to become an important alternative in the management of patients with end-stage pulmonary disease and chronic respiratory failure. The beginnings of this technique can be traced back to the experiments of Carrel and Guthrie over a hundred years ago. However, it was not until 1963 when the first clinical experience was performed by Hardy. Clinical success did not arrive until the 1980's thanks to the works of the Toronto Lung Transplant Group. Well established criteria have been described in order to consider a patient as a potential candidate to receive a lung. Several diseases are capable of causing terminal lung damage and in general they can be classified according to their origin as obstructive (COPD, emphysema), restrictive (fibrosis), chronic infectious (cystic fibrosis, bronquiectasis), and vascular (primary pulmonary hypertension). The most frequent diagnosis is COPD. Clinically relevant modes of LT include the implant of one lung (single LT), or both lungs (bilateral sequential LT). Transplantation of the cardiopulmonary block is reserved for special situations and lobar transplantation is still considered experimental. Donor condition is essential to the success of LT. The potential donor patient frequently suffers deterioration in lung function due to edema formation or infection and both complications restrict lung's using for transplantation. Lung preservation is also limited to a short period of time which rarely exceeds 6 hours in spite of specially-designed preservative solutions such as the low potassium dextran. Outcome after LT shows current one-year survival between 65-70% with reduction to 40-45% after five years. Mortality within the first year is usually related to primary graft failure and infection. Long-term survival depends on controlling infectious problems due to immunosuppression as well as the development of bronchilitis obliterans as a manifestation of chronic rejection. LT is a therapeutic modality reserved for selected patients with chronic respiratory failure due to end-stage lung disease.